Prof. Hideyuki Akaza
The
University of Tokyo, Japan
Email:
akazah@med.rcast.u-tokyo.ac.jp
Qualifications
1980 M.Sc., The University
of Tokyo,
Japan
1973 B.Sc., The University
of Tokyo, Japan
Publications (Selected)
-
Hideyuki
Akaza, ShiroHinotsu, MichiyukiUsami, Yoichi Arai, Hiroshi Kanetake, Seiji
Naito, Yoshihiko Hirao, Study Group for the Combined Androgen Blockade Therapy
of Prostate Cancer. Combined Androgen Blockade WithBicalutamide for Advanced
Prostate Cancer: Long-Term Follow-Up of a Phase 3, Double-Blind, Randomized
Study for Survival. Cacner 2009; 115:3437-3445.
-
Matthew
R. Cooperberg, ShiroHinotsu, MikioNamiki, Kazuto Ito, Jeanette Broering, Peter
R. Carroll, Hideyuki Akaza. Risk Assessment Among Prostate Cancer Patients
Receiving Primary Androgen Deprivation Therapy. J ClinOncol 2009;27: 4306-4313
-
Lamm
D, Böhle A, Palou J, Persad R, Brausi M, Colombel M, Akaza H, Buckley R.
Re: Per-Uno Malmström, Richard J. Sylvester, David E.
Crawford, et al. An individual patient data meta-analysis of the long-term
outcome of randomised studies comparing intravesicalmitomycin C versus bacillus
Calmette-Guerin for non-muscle-invasive bladder cancer. EurUrol 2009;
56:247-56. Eur Urol.2010; 57: e7-9.
-
Akaza
H. Current Asia Pacific Anticancer Therapy and
Research Initiatives and Strategies.Jpn J ClinOncol. 2010; 40(Suppl 1): i1.
-
Akaza
H, Hill D, Roh JK, Hao XS. Proposal on the Establishment of Infrastructure for
Providing Cancer Treatment in Asia in the
Context of Global Health Asia-Pacific Cancer Conference (12-14 November 2009).
Jpn J ClinOncol. 2010; 40: i86-i92.
-
Naito
S, Tsukamoto T, Murai M, Fukino K, Akaza H. Overall survival and good
tolerability of long-term use of sorafenib after cytokine treatment: final
results of a phase II trial of sorafenib in Japanese patients with metastatic
renal cell carcinoma. BJU Int. 2011; 108: 1813-9.
-
Hinotsu
S, Akaza H, Naito S, Ozono S, Sumiyoshi Y, Noguchi S, Yamaguchi A, Nagamori S,
Terai A, Nasu Y, Kume H, Tomita Y, Tanaka Y, Samma S, Uemura H, Koga H,
Tsushima T. Maintenance therapy with bacillus Calmette-Guérin Connaught strain
clearly prolongs recurrence-free survival following transurethral resection of
bladder tumour for non-muscle-invasive bladder cancer. BJU Int. 2011; 108:
187-95.
-
Miyazaki
J, Kawai K, Kojima T, Oikawa T, Joraku A, Shimazui T, Nakaya A, Yano I,
Nakamura T, Harashima H, Akaza H. The liposome-incorporating cell wall skeleton
of Mycobacterium bovis bacillus Calmette-Guéin can directly enhance the
susceptibility of cancer cells to lymphokine-activated killer cells through
up-regulation of natural-killer group 2, member D ligands. BJU Int. 2011;
108:1520-1526.
-
Tsukamoto
T, Shinohara N, Tsuchiya N, Hamamoto Y, Maruoka M, Fujimoto H, Niwakawa M,
Uemura H, Usami M, Terai A, Kanayama HO, Sumiyoshi Y, Eto M, Akaza H. Phase III
trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of
Japanese patients from RECORD-1. Jpn J ClinOncol. 2011; 41:17-24.
-
Akaza
H, Kanetake H, Tsukamoto T, Miyanaga N, Sakai H, Masumori N, Nakatsu H,
Sagiyama K, Sakamoto S, Endo Y, Yamanouchi T; REDUCE Study Group. Efficacy and
safety of dutasteride on prostate cancer risk reduction in Asian men: the
results from the REDUCE study. Jpn J ClinOncol. 2011; 41: 417-23.
-
Akaza
H, Tsukamoto T, Fujioka T, Tomita Y, Kitamura T, Ozono S, Miki T, Naito S,
Zembutsu H, Nakamura Y. Combined immunotherapy with low-dose IL-2 plus
IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected
patients with lung metastasis and serum sodium level. Jpn J ClinOncol. 2011;
41: 1023-30.
-
Tsuji
H, Moriyama K, Nomoto K, Akaza H. Identification of an Enzyme System for
Daidzein-to-Equol Conversion in Slackia sp. Strain NATTS. Appl Environ
Microbiol 2012; 78: 1228-36.
-
Akaza
H. Prostate Cancer Chemoprevention by Soy Isoflavones-Role of intestinal
bacteria as the "second human genome". Cancer Sci 2012; 103: 969-75.
-
Miyanaga
N, Akaza H, Hinotsu S, Fujioka T, Naito S, Namiki M, Takahashi S, Hirao Y,
Horie S, Tsukamoto T, Mori M, Tsuji H. Prostate cancer chemoprevention study:
an investigative randomized control study using purified isoflavones in men
with rising prostate-specific antigen. Cancer Sci.2012; 103: 125-30.
-
Hinotsu
S, Kawai K, Ozono S, Tsushima T, Tokuda N, Nomata K, Naito S, Akaza H.
Randomized controlled study of natural interferon α as adjuvant treatment for
stage II or III renal cell carcinoma. Int J ClinOncol. 2012; [Epub ahead of
print]
-
Akaza
H, Carroll P, Cooperberg MR, Hinotsu S. Fifth Joint Meeting of J-CaP and
CaPSURE: Advancing the Global Understanding of Prostate Cancer and Its Management.2012;
42: 226-36.
-
Ozono
S, Ueda T, Hoshi S, Yamaguchi A, Maeda H, Fukuyama Y, Takeda K, Ohashi Y,
Tsukamoto T, Naito S, Akaza H. The Efficacy and Safety of Degarelix, a GnRH
Antagonist: A 12-month, Multicentre, Randomized, Maintenance Dose-finding Phase
II Study in Japanese Patients with Prostate Cancer. Jpn J ClinOncol 2012; 42:
477-84.